P006: MiR-192 is associated with stricturing phenotype in Crohn’s diseaseECCO'22Year: 2022
Authors: Cristina, T.(1);Mateescu, B.(2);Mitroi, A.(3);Cozaru, G.(3);Brinzan, C.(3);State, M.(2);Dumitru, A.(1);Rafti, R.(1);Dina, E.(1);Alexandrescu, L.(1);Dumitru, E.(1);
(1)County Clinical Emergency Hospital of Constanta, Gastroenterology, Constanta, Romania;(2)Clinical Hospital Colentina Bucharest, Gastroenterology, Bucharest, Romania;(3)County Clinical Emergency Hospital of Constanta, Genetics, Constanta, Romania;
P007: ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagyECCO'22Year: 2022
Authors: Tran, F.(1,2);Stengel, S.(2);Yang, H.(2);Bernardes, J.P.(2);Lopez-Agudelo, V.(2);Bordoni, D.(2);Falk-Paulsen, M.(2);Jentzsch, M.(2);Messner, B.(2);Schreiber, S.(1,2);Rosenstiel, P.(2);
(1)University Medical Center- Schleswig-Holstein- Kiel Campus, Department for Internal Medicine I, Kiel, Germany;(2)University Medical Center- Schleswig-Holstein- Kiel Campus, Institute of Clinical Molecular Biology, Kiel, Germany;
P008: Modulation of Wnt signaling via a Wnt mimetic improved epithelial healing without causing hyperplasia in a mouse colitis modelECCO'22Year: 2022
Authors: Lu, C.(1);Xie, L.(2);Shah, D.(1);Newman, M.(3);Baribault, H.(2);Yeh, W.C.(2);Li, Y.(1);
(1)Surrozen Inc., Discovery Biology, South San Francisco, United States;(2)Surrozen Inc., in vivo Pharmacology, South San Francisco, United States;(3)Surrozen Inc., Development, South San Francisco, United States;
P009: Integrin-b7+ cytotoxic MAIT cells are expanded in the colon of Ulcerative Colitis patients, correlate with disease severity and are targeted by vedolizumab therapy.ECCO'22Year: 2022
Authors: Hermangild Kottoor, S.(1);ibraheim, H.(1);Polychronis, P.(2);Senthuran, B.(2);Jameson, E.(2);Samaan, M.(2);Irving, P.(2);Powell, N.(1);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Guy's & St. Thomas' NHS Foundation Trust, IBD Centre, London, United Kingdom;
P010: Adherent-Invasive Escherichia Coli strain O83:H1 induces inflammatory response in Crohn's diseaseECCO'22Year: 2022
Authors: Iaquinto, G.C.(1);Mazzarella, G.(2);Rotondi Aufiero, V.(3);
(1)Clinica S. Rita, Gastroenterology, Atripalda, Italy;(2)Institute of Food Sciences- ISA- CNR, DiSBA, Avellino, Italy;(3)Institute of Food Sciences- ISA-CNR, DiSBA, Avellino, Italy;
P011: New insights into the pathogenic potential and signalling network of NKG2D+ CD4+ T-cells in Crohn’s DiseaseECCO'22Year: 2022
Authors: Modos, D.(1,2);Gul, L.(1);Lo, J.(3,4);Madgwick, M.(1);Cozzetto, D.(3);Lord, G.(5,6);Korcsmaros, T.(1,2,3);Powell, N.(3,4);
(1)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(2)Quadram Institute Bioscience, Gut Microbes and Health, Norwich, United Kingdom;(3)Imperial College-Faculty of Medicine, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(4)King's College, Centre for Inflammation Biology & Cancer Immunology, London, United Kingdom;(5)Manchester University, Faculty of Biology- Medicine and Health, Manchester, United Kingdom;(6)King's College, School of Immunology and Microbial Sciences, London, United Kingdom;
P012: The effect of Oncostatin M on human intestinal organoidsECCO'22Year: 2022
Authors: Filidou, E.(1);Kandilogiannakis, L.(1);Kokkotis, G.(2);Tarapatzi, G.(1);Arvanitidis, K.(1);Drygiannakis, I.(3);Valatas, V.(3);Paspaliaris, V.(4);Kolios, G.(1);Bamias, G.(2);
(1)Laboratory of Pharmacology- Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece;(2)GI Unit- 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece;(3)Laboratory of Gastroenterology, University of Crete, Herakleion, Greece;(4)Tithon Biotech, Inc, San Diego, United States;
P013: A single cell approach reveals immune cell dynamics in Inflammatory Bowel Disease (IBD) and highlights association of CD8 intraepithelial lymphocytes (IELs) with response to vedolizumab treatmentECCO'22Year: 2022
Authors: Paraskevopoulou, M.(1);Mayer, L.(2);Krueger, A.(1);Pattekar, A.(3);Ramos, A.(3);Fulton, M.(3);Wai Lau, C.(3);Chau, L.(3);Ren, Y.(3);Tondon, R.(3);Al Garawi, A.(1);Bittinger, K.(4);Fogt, F.(3);Yajnik, V.(1);Lee, H.(3);Lewis, J.(3);Wu, G.(3);Bewtra, M.(3);Tomov, V.(3);Juarez, J.(1);
(1)Takeda Pharmaceuticals U.S.A., Inc., Lexington, United States;(2)Department of Medicine II- Gastroenterology- Hepatology- Endocrinology- and Infectious Diseases- Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany;(3)Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States;(4)The Children's Hospital of Philadelphia, Philadelphia, Philadelphia, United States;
P014: Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmissionECCO'22Year: 2022
Authors: Faggin, S.(1);Cerantola, S.(1);Dal Prà, A.(1);Caldana, G.(1);Bosi, A.(2);Banfi, D.(2);Giaroni, C.(2);Savarino, E.(3);Giron, M.C.(1);
(1)University of Padova, Department of Pharmaceutical and Pharmacological Sciences, Padova, Italy;(2)University of Insubria, Department of Medicine and Surgery, Varese, Italy;(3)University of Padova, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;
P015: Detection of endoscopic lesions from limited quality annotations in colonoscopy videosECCO'22Year: 2022
Authors: Alali, S.(1);Chaussard, J.(1);Li-Thiao-Té, S.(1);Ogier-Denis, É.(2);Percy-du-sert, A.(3);Treton, X.(3);Zaag, H.(1);
(1)Université sorbonne Paris Nord, Laboratoire Analyse- Géométrie et Applications, Villetaneuse, France;(2)Institut national de la santé et de la recherche médicale-INSERM, Paris, Paris, France;(3)Hôpital Beaujon Gastro-enterologie et assisstance nutritive, Hauts de seine, Clichy, France;
P016: Colonoids derived from UC patients retain higher transcriptional response to inflammatory triggers in-vitro, even after several passagesECCO'22Year: 2022
Authors: Abbas Egbariya, H.(1);Ben-Shoshan, M.(2);Braun, Z.(2);Berger, T.(2);granot, M.(2);Loberman-Nachum, N.(2);Vais, B.(2);Gal Mor, O.(1);Amir, A.(2);Haberman, Y.(2);
(1)Tel Aviv university - faculty of medicine, microbiology, tel aviv, Israel;(2)Sheba medical center, pediatric gastroenterology, Ramat Gan, Israel;
P017: Transcriptional characterization of lymphocytic colitis and comparison to collagenous colitisECCO'22Year: 2022
Authors: Koch, S.(1);Münch, A.(2);Escudero-Hernández, C.(1,3);
(1)Linköping University, Department of Biomedical and Clinical Sciences BKV, Linköping, Sweden;(2)Linköping University, Department of Biomedical and Clinical Sciences BKV- Department of Gastroenterology and Hepatology- and Department of Health- Medicine- and Caring Sciences, Linköping, Sweden;(3)Current address: Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein- Kiel- Germany, Institute for Clinical Molecular Biology- IKMB, Kiel, Germany;
P018: Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discoveryECCO'22Year: 2022
Authors: Baldan-Martin, M.(1);Azkargorta , M.(2);Iloro , I.(2);Ortega Moreno , L.(1);Aldars Garcia , L.(1);Soleto Fernández , I.(1);Ramirez , C.(1);Riestra , S.(3);Rivero , M.(4);Gutierrez , A.(5);Rodríguez-Lago , I.(6);Fernández-Salazar , L.(7);Ceballos , D.(8);Benítez , J.M.(9);Aguas , M.(10);Bastón-Rey , I.(11);Bermejo , F.(12);Casanova , M.J.(1);Llorente , R.(13);Ber , Y.(14);Royo , V.(15);Esteve , M.(16);Elortza , F.(2);Chaparro , M.(1);Gisbert , J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Proteomics Platform- CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd- ProteoRed-ISCIII, Proteomics Platform, Derio, Spain;(3)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(4)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(5)Hospital General Universitario de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(6)Hospital Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(7)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(8)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(9)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(10)Hospital Universitari i Politecnic La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain;(11)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(12)Hospital Universitario de Fuenlabrada and IDIPAZ, Gastroenterology Unit, Madrid, Spain;(13)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(14)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(15)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(16)Hospital Universitari Mutua Terrasa and CIBERehd, Gastroenterology Unit, Terrasa, Spain;
P019: GS-1069518 is a potent and selective small molecule α4β7 inhibitorECCO'22Year: 2022
Authors: Wang, Y.(1);Zhou, J.(2);Chang, C.(3);Roedder, S.(3);Bonne-Annee, S.(1);Marchand, B.(4);Hung, K.(4);Currie, K.(5);Clarke, A.(1);
(1)Gilead Sciences- Inc., Inflammation Biology, Seattle, United States;(2)Gilead Sciences- Inc., Oncology Biology, Seattle, United States;(3)Gilead Sciences- Inc., Biomarkers, Foster City, United States;(4)Gilead Sciences- Inc., Discovery Sciences, Foster City, United States;(5)Gilead Sciences- Inc., Medicinal Chemistry, Seattle, United States;
P020: Differential expression of miR-424-5p and miR-378c in stenotic and penetrating lessions of Crohn’s Disease associates with altered transcription of genes involved in vascular regulationECCO'22Year: 2022
Authors: Coll, S.(1);Seco, M.(1);Bauset, C.(1);Lis, L.(1);Cosín-Roger, J.(2);Ortiz-Masia, D.(3);Gisbert-Ferrandiz, L.(1);Barrachina, D.(1);Calatayud, S.(1);
(1)Faculty of Medicine - University of Valencia, Pharmacology, Valencia, Spain;(2)FISABIO, Unidad Mixta Facultad de Medicina-Hospital Dr Peset, Valencia, Spain;(3)Faculty of Medicine - University of Valencia, Medicine, Valencia, Spain;
P021: Vitamin D receptor-dependent protective effect of moderate hypoxia in a mouse colitis model Running title: Hypoxia prevents mouse colitis through VDRECCO'22Year: 2022
Authors: Wang, Z.(1);Hong, Y.(2);Hong, L.(3);Changzhi, H.(4);Jiaming, Q.(3);
(1)Peking Union Medical College Hospital, Gastroenterology, Beijing- China, China;(2)Peking Union Medical College Hospital, Gastroenterology, Beijng, China;(3)Peking Union Medical College Hospital, Gastroenterology, Beijing, China;(4)Cancer Hospital- CAMS and PUMC, State Key Laboratory of Molecular Oncology, Beijing, China;
P022: Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis.ECCO'22Year: 2022
Authors: Arosa García, L.(1);Camba-Gómez, M.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto , M.(2);Nieto-García , L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta , M.(2);Conde-Aranda, J.(1);
(1)Health Research Institute of Santiago de Compostela IDIS, Molecular and Cellular Gastroenterology, Santiago de Compostela, Spain;(2)University Hospital of Santiago de Compostela, Department of Gastroenterology and Hepatology, Santiago de Compostela, Spain;Molecular and Cellular Gastroenterology
P024: CD40 and key CD40/CD154 pathway members are significantly upregulated in inflamed lesional IBD biopsies as shown by whole transcriptome AmpliSeq gene expression profiling and corresponding immunohistochemistry.ECCO'22Year: 2022
Authors: Raulf, F.(1);Delucis-Bronn, C.(1);Angevaare, E.(1);Caesar, N.(1);Marcantonio, A.(1);Ceci, M.(1);Regnier, C.(1);Bonal, C.(2);Siegel, R.(2);Niess, J.H.(3);Wieczorek, G.(1);Hrúz, P.(3);
(1)Novartis Pharma AG / Novartis Institutes for BioMedical Research, Autoimmunity- Transplantation and Inflammation Disease Area, Basel, Switzerland;(2)Novartis Pharma AG / Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland;(3)Clarunis AG, University Center for Gastrointestinal and Liver Diseases, Basel, Switzerland;
